By Lucy Parkinson, Director of Research, LSN
One of the key shifts in the life science product development landscape in recent years is that big pharma companies are increasingly looking outward for innovation. Pharma corporate development groups are deploying an array of means to source, evaluate and invest in assets discovered or developed by biotech entrepreneurs.
At RESI San Francisco, the Big Pharma panel will explore the shifting dynamic between big pharma and small biotechs. What can you expect from a pharma company’s evaluation process, and what can you do to position your startup to make a deal? Panelists will answer these questions and provide their advice on how entrepeneurs can take align themselves with the firms that they represent.
Moderated by Kevin Lynch, Vice President, Scientific Assessment, AbbVie, the panelists are:
- Habib Dable, President of US Pharmaceuticals, Bayer Healthcare Pharmaceuticals
- Jason Coloma, Vice President, Global Head Roche Partnering Oncology, Roche
- Lesley Stolz, Senior Director of Transactions, Johnson & Johnson Innovation
- Tomas Landh, Vice President, Strategy and Innovation Sourcing, Novo Nordisk
If you’d like to hear this panel live at RESI and meet with investors from the pharma world and beyond, you can register for RESI San Francisco now.
Next Phase Newsletter 
Leave a comment